PLEASANTON, Calif., Jan. 30, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of the full Veeva Compass Suite of commercial data products for a more complete view into patient populations and HCP-level insight. Veeva Compass Prescriber and Veeva Compass National are the first to deliver projections for both retail prescriptions and complex procedures, including in-office administered therapies, injections, and infusions. Veeva Compass Suite also includes Compass Patient, granular, longitudinal patient data spanning prescriptions, procedures, and diagnoses. Veeva Compass products are licensed by the brand and give brands unlimited data access, including historical data.
"Veeva Compass Suite delivers the data the industry needs for a faster, more precise approach to commercialization," said Mike Rifflard, vice president, operations, rare disease, ANI Pharmaceuticals. "With Veeva Compass, we accelerated our product launch by giving field teams a more complete and timely view of our customers."
Veeva Compass data products are available for the U.S. market today and include:
"The availability of the full Veeva Compass Suite of data products is a major milestone for the industry and for Veeva," said Peter Stark, executive vice president and general manager, Veeva Compass. "We are excited to deliver significant innovations in commercial data for life sciences. Powered by a simple, modern data architecture, Veeva Compass handles both retail and complex therapies for more than 4,000 brands."
Additional Information For more on Veeva Compass, visit: veeva.com/Compass
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As aPublic Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visitveeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$210.63 |
Daily Change: | 0.74 0.35 |
Daily Volume: | 1,135,895 |
Market Cap: | US$34.110B |
November 20, 2024 November 19, 2024 October 24, 2024 September 05, 2024 September 05, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB